Key Points
- CEO William Lewis sold 10,699 shares on March 5 at an average price of $146.03 for about $1.56 million, reducing his stake by 3.43% to 301,185 shares (≈$43.98M).
- This transaction is part of a string of recent insider sales since December (including multiple trades in January and February), representing tens of thousands of shares sold by the CEO over the past months.
- Insmed recently missed earnings (Q report: EPS -$1.54 vs. -$1.07 expected) while reporting $263.84M revenue and a deeply negative net margin (-210.54%); the stock trades around $143.44 and carries a consensus "Buy" rating with an average analyst price target of $207.52.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of Insmed stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $146.03, for a total value of $1,562,374.97. Following the completion of the sale, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,982,045.55. The trade was a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
William Lewis also recently made the following trade(s):
- On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $150.97, for a total transaction of $1,615,228.03.
- On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84.
- On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total transaction of $470,427.06.
- On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.
- On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
- On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
- On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $412,639.99.
- On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
- On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total value of $1,786,412.03.
Insmed Stock Performance
NASDAQ INSM traded down $0.13 on Friday, reaching $143.44. The stock had a trading volume of 436,440 shares, compared to its average volume of 2,502,834. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock has a market cap of $30.92 billion, a P/E ratio of -22.38 and a beta of 1.13. The business's 50-day moving average price is $159.34 and its 200 day moving average price is $165.22. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75.
Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business's revenue was up 152.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.32) earnings per share. As a group, equities analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages have recently weighed in on INSM. HC Wainwright reiterated a "buy" rating and set a $230.00 target price on shares of Insmed in a research note on Monday, February 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Insmed in a research note on Thursday, January 22nd. Barclays started coverage on Insmed in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $231.00 target price on the stock. Leerink Partners reissued an "outperform" rating on shares of Insmed in a report on Thursday, December 18th. Finally, Cantor Fitzgerald increased their price target on Insmed from $216.00 to $230.00 and gave the stock an "overweight" rating in a report on Tuesday, December 16th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $207.52.
Check Out Our Latest Research Report on Insmed
Institutional Trading of Insmed
A number of institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new position in shares of Insmed during the 4th quarter worth approximately $27,000. Stone House Investment Management LLC purchased a new stake in Insmed in the 3rd quarter valued at approximately $29,000. SBI Securities Co. Ltd. grew its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC acquired a new stake in Insmed during the 4th quarter valued at $30,000.
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
